Extrait

Background and study aims Helicobacter pylori is a bacterial infection that increases the risk of stomach cancer. The aim of this study is to find out whether screening for and eradicating H. pylori infection in healthy middle aged people can reduce the subsequent incidence of stomach cancer. Who can participate? Men aged 35-69 and women aged 45-69 attending a Bupa Wellness Centre for a health screen. What does the study involve? Participants are randomly allocated to one of two groups. Participants in one group are tested for H. pylori and, if found to be infected, are offered a one-week course of drug treatment to eradicate the infection (oral metronidazole, clarithromycin and lansoprazole). Participants in the other group do not receive any screening or treatment. All participants are followed up for 15 years or more to assess the incidence of deaths from stomach cancer. What are the possible benefits and risks of participating? Not provided at time of registration Where is the study run from? Queen Mary, University of London (UK) When is the study starting and how long is it expected to run for? April 1997 to January 2021 Who is funding the study? 1. Cancer Research UK (CRUK) (UK) 2. Bupa Foundation (UK) Who is the main contact? Prof. Nicholas Wald

Critère d'inclusion

• Prevention of stomach cancer

Liens

• isrctn
• ictrp